Trial Profile
A Phase II Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Hyaluronidase/rituximab (Primary) ; Rituximab (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 30 Nov 2023 Planned End Date changed from 15 Oct 2023 to 1 Oct 2024.
- 30 Nov 2023 Planned primary completion date changed from 15 Oct 2023 to 1 Oct 2024.
- 14 Mar 2022 Status changed from recruiting to active, no longer recruiting.